At the same time, we also found that the anti-inflammatory effect of TBIL may be reflected by inhibiting TNF-α levels, which leads to the decrease of CRP level and decrease of complement consumption, making the decrease of TBIL a risk factor for SLE aggravation (30–33). Here, CRP is linked to systemic lupus erythematosus.